Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants

As new SARS-CoV-2 variants continue to emerge, it is important to evaluate the potency of antiviral drugs to support their continued use. Remdesivir (RDV; VEKLURY<sup>®</sup>) an approved antiviral treatment for COVID-19, and obeldesivir (ODV) are inhibitors of the SARS-CoV-2 RNA-depende...

Full description

Saved in:
Bibliographic Details
Main Authors: Lauren Rodriguez, J. Lizbeth Reyes Zamora, Dong Han, Jasmine Moshiri, Nadine Peinovich, Clarissa Martinez, Pui Yan Ho, Jiani Li, Thomas Aeschbacher, Ross Martin, Andrew Pekosz, John P. Bilello, Jason K. Perry, Charlotte Hedskog
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Viruses
Subjects:
SARS-CoV-2
COVID-19
Omicron variants
remdesivir
genotyping
phenotyping
Online Access:https://www.mdpi.com/1999-4915/17/2/168
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4915/17/2/168

Similar Items